EATONTOWN, N.J. — (MEDIA ADVISORY) — April 8, 2014 — American CryoStem Corporation (OTCQB: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at the BioNJ International BioPartnering Conference to be held at The Westin Princeton at Forrestal Village in Princeton, NJ on April 10, 2014.
The Conference will include partnering sessions, company presentations and speaker sessions with top-level executives from leading biotechnology, pharmaceutical and research industries. Participants will have an opportunity to showcase their companies, meet potential funders, and network with other biotechnology companies from New Jersey and around the world.
“We have advanced our standardized stem cell platform and development activities to the point where we are actively seeking stragetic collobaratoins,” commented Anthony Dudzinski, COO of American CryoStem. “This conference will allow us to present our cutting-edge stem cell platform to leading pharmaceutical and biotechnology companies that have the capability to significantly accelerate our development of cellular therapies and treatments,” continued Dudzinski.
EVENT AT A GLANCE
WHO: Anthony Dudzinski – COO
WHEN: Thursday, April 10, 2014 11:00 to 11:15 AM
WHERE: The Westin Princeton at Forrestal Village
201 Village Boulevard
With more than 300 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey’s biotechnology cluster. Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate in New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem operates a state-of-the-art, FDA-registered, clinical laboratory dedicated to processing, bio-banking and development of cellular applications using autologous adipose (fat) tissue and adipose derivered stem cells (ADSCs). Through its scientific efforts, the Company has built a strong, strategic portfolio of intellectual property, patent applications, and proprietary operating processes that form its core standardized cellular platform. For more information, please visit www.americancryostem.com and www.acslaboratories.com. You can also find us on Facebook and Twitter.